ROTUNNO, GIADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.450
EU - Europa 3.367
AS - Asia 2.166
SA - Sud America 295
Continente sconosciuto - Info sul continente non disponibili 142
AF - Africa 53
OC - Oceania 19
Totale 11.492
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.365
RU - Federazione Russa 1.086
IT - Italia 772
SG - Singapore 636
CN - Cina 597
PL - Polonia 480
HK - Hong Kong 303
BR - Brasile 236
IE - Irlanda 219
VN - Vietnam 199
SE - Svezia 183
KR - Corea 168
DE - Germania 128
FR - Francia 115
FI - Finlandia 113
GB - Regno Unito 84
CH - Svizzera 70
IN - India 59
CA - Canada 57
JO - Giordania 40
BD - Bangladesh 36
NL - Olanda 33
ID - Indonesia 25
AR - Argentina 23
ES - Italia 23
AU - Australia 19
IQ - Iraq 17
JP - Giappone 14
PK - Pakistan 13
CI - Costa d'Avorio 12
MX - Messico 11
UZ - Uzbekistan 10
EC - Ecuador 9
UA - Ucraina 9
AT - Austria 8
BE - Belgio 8
NG - Nigeria 8
ZA - Sudafrica 8
BG - Bulgaria 7
KE - Kenya 7
TW - Taiwan 7
PH - Filippine 6
PY - Paraguay 6
SA - Arabia Saudita 6
TN - Tunisia 6
TR - Turchia 6
VE - Venezuela 6
CO - Colombia 5
CR - Costa Rica 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
HU - Ungheria 4
MY - Malesia 4
AL - Albania 3
CL - Cile 3
EG - Egitto 3
LV - Lettonia 3
MA - Marocco 3
RO - Romania 3
BJ - Benin 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
IL - Israele 2
KZ - Kazakistan 2
MT - Malta 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PR - Porto Rico 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BT - Bhutan 1
BY - Bielorussia 1
CU - Cuba 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
HN - Honduras 1
HR - Croazia 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LT - Lituania 1
NI - Nicaragua 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
YT - Mayotte 1
Totale 11.353
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.091
Ashburn 658
Warsaw 473
Singapore 432
Fairfield 414
Hong Kong 259
Woodbridge 227
Chandler 222
Dublin 219
Seattle 202
San Jose 172
Seoul 168
Cambridge 158
Houston 158
Wilmington 147
Beijing 145
Florence 116
Ann Arbor 112
Hefei 105
Milan 98
Altamura 82
Lawrence 80
Los Angeles 77
Buffalo 73
Bern 70
Ho Chi Minh City 62
Princeton 60
The Dalles 60
Dallas 57
Munich 52
Lauterbourg 51
New York 50
Helsinki 48
Hanoi 42
Boston 40
Rome 40
Moscow 34
Turku 34
Shanghai 32
Council Bluffs 31
Bremen 30
London 29
San Diego 29
Mumbai 27
Clifton 26
Paris 26
São Paulo 26
Kent 24
Medford 21
Atlanta 19
Melbourne 18
Boardman 17
Naples 17
Orem 17
Redondo Beach 17
Barcelona 15
Jakarta 15
Montreal 15
Abidjan 12
Brooklyn 12
Dearborn 12
Dong Ket 12
Amsterdam 11
Hillsboro 11
Tokyo 11
Frankfurt am Main 10
Tashkent 10
Turin 10
Brescia 9
Norwalk 9
Palermo 9
Abuja 8
Brussels 8
Chennai 8
Chicago 8
Claymont 8
Da Nang 8
Figino 8
Fuzhou 8
Guangzhou 8
Hangzhou 8
Baghdad 7
Cagliari 7
Johannesburg 7
Nairobi 7
Phoenix 7
Pune 7
Toronto 7
Biên Hòa 6
Dhaka 6
Fiesole 6
Haiphong 6
Manchester 6
Pian di Scò 6
San Francisco 6
Tianjin 6
Venice 6
Vienna 6
Belo Horizonte 5
Bologna 5
Totale 7.376
Salva come PNG Salva come JPEG
Nome #
Study of mutation complexity in Chronic Myeloproliferative Neoplasms: pathogenetic insights and translational relevance 403
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 400
Validation of the Mayo alliance prognostic system for mastocytosis 343
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 334
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 308
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 291
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 249
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 248
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 248
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 230
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 230
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 227
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 221
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 217
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 210
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 209
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 207
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 202
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 200
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 199
Mutations and prognosis in primary myelofibrosis. 198
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 198
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 197
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 197
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 196
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 194
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 192
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 187
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 184
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 183
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 183
CALR mutation burden in essential thrombocythemia and disease outcome 179
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 179
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 177
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 176
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 172
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 170
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 165
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 163
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 160
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 160
Prognotic Impact of Mutations in Systemic Mastocytosis 156
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 155
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 154
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 153
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? 152
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 151
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 150
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 150
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML 146
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 139
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 138
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 138
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients 133
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 133
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 128
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting 117
Prognostic relevance of mutations in myelofi-brosis 115
null 47
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia. 38
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis 13
Totale 11.492
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.226
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.226
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022370 0 8 48 17 20 21 13 40 20 14 74 95
2022/20231.160 87 228 72 79 71 173 140 89 103 13 26 79
2023/2024481 25 40 64 18 51 60 12 102 11 32 34 32
2024/20253.139 84 283 196 502 845 494 72 144 130 101 141 147
2025/20263.369 423 408 302 322 384 122 377 119 207 226 127 352
2026/2027503 163 340 0 0 0 0 0 0 0 0 0 0
Totale 11.492